Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF, Ruiz-Patiño A, Recondo G, Martín C, Raez L, Samtani S, Minata JN, Blaquier JB, Enrico D, Burotto M, Ordóñez-Reyes C, Chamorro DF, Garcia-Robledo JE, Corrales L, Zatarain-Barrón ZL, Más L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Rodríguez J, Archila P, Bermudez M, Gamez T, Cordeiro de Lima V, Freitas H, Russo A, Polo C, Malapelle U, Perez DM, Rolfo C, Viola L, Rosell R, Arrieta O.
Cardona AF, et al. Among authors: sotelo c.
Clin Lung Cancer. 2022 Sep;23(6):522-531. doi: 10.1016/j.cllc.2022.06.001. Epub 2022 Jun 6.
Clin Lung Cancer. 2022.
PMID: 35798634